Jhaveri, Kenar D. http://orcid.org/0000-0003-1578-0524
Bensink, Mark E.
Bunke, Martin
Briggs, Jonathon A.
Cork, David M. W.
Jeyabalan, Anushya
Funding for this research was provided by:
Travere Therapeutics, Inc
Article History
Accepted: 4 April 2023
First Online: 27 April 2023
Declarations
:
: This study was funded by Travere Therapeutics, Inc.
: KDJ is a founder and co-president of the American Society of Onco-Nephrology; reports consultancy agreements with Secretome, George Clinicals, PMV pharmaceuticals and Calliditas; reports honoraria from the American Society of Nephrology, the International Society of Nephrology, and UpToDate.com; reports serving on the editorial boards of American Journal of Kidney Diseases, CJASN, Clinical Kidney Journal, Journal of Onconephrology, Kidney International, and Nephrology Dialysis Transplantation; reports serving as Editor-in-Chief of ASN Kidney News and section editor for onconephrology for Nephrology Dialysis Transplantation. MEB is a consultant for Travere Therapeutics, Inc. and reports an additional consultancy with Amgen, Inc.; MB is a consultant for Travere Therapeutics, Inc.; JAB and DMWC are employees of Genesis Research, which received compensation from Travere Therapeutics, Inc. for conducting this study. AJ declared that they have no conflict of interest.
: All data supporting the findings of these systematic literature reviews are available within the article. All data were obtained from the references included and cited in these reviews.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Study design and concept: Mark Bensink, Martin Bunke, David Cork. Evidence synthesis including search strategy development, abstract and full text screening, and data validation: Jonathon Briggs, David Cork. All authors contributed to interpretation of results, writing and/or review of manuscript drafts, and approved the final manuscript.